CRVO

CervoMed Inc.
CAPPED RATING

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.

CervoMed Inc. (CRVO) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Growth (C+); its weakest is Value (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.7 / 5.0
D+
Value
F
Factor Score 0.0 / 5.0
Growth
C+
Factor Score 2.7 / 5.0
Profitability
C-
Factor Score 2.0 / 5.0
Momentum
D
Factor Score 1.2 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -1.2
EV / EBITDA N/A
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -55.4%
Price Return 12M -80.2%
Catalyst Signal 0.00
Market Cap $20.7M
TTM Revenue $8.7K
Price / Sales 2.4K
ROE -131.5%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-11 F (0.0) C+ (2.7) C- (2.0) D (1.2) C+ (2.6) D+ (1.7)
2026-11-04 C+ (2.6) B- (3.1) C (2.2) D+ (1.7) C+ (2.7) C (2.5)
2026-10-28 C (2.4) B- (2.9) C (2.2) C- (2.0) C+ (2.7) C (2.4)
2026-10-21 C (2.4) B- (2.9) C (2.2) D+ (1.7) C+ (2.6) C (2.4)
2026-10-14 C (2.4) B- (2.9) C (2.2) D+ (1.6) C+ (2.6) C (2.4)
Page 1 of 6